Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of TruBridge, Inc. due to allegations of materially misleading business information issued by the company [1] Group 1: Legal Action and Investor Rights - Shareholders who purchased TruBridge securities may be entitled to compensation through a class action without any out-of-pocket fees [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2] Group 2: Financial Reporting Issues - TruBridge filed a Notification of Late Filing on Form 12b-25, indicating its inability to file its Annual Report for the fiscal year ended December 31, 2025, due to the identification of out-of-period errors in previously issued financial statements [3] - The errors identified relate to revenue recognition, contract costs, stock-based compensation expenses, and capitalized software development expenses, necessitating revisions to financial statements for the years ended December 31, 2024, and December 31, 2023 [3] - Following this announcement, TruBridge's stock price fell by $1.84 per share, or 10.5%, closing at $15.75 per share on March 17, 2026 [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Hitek Global Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is focused on potential civil securities claims against Hitek Global Inc. [3]. - Shareholders who purchased Hitek securities may be entitled to compensation through a class action without any out-of-pocket fees [2]. Group 2: Class Action Information - Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Hitek Global Inc. [2]. - Interested parties can join the prospective class action by visiting the provided link or contacting the firm directly [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked highly for its number of securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Group 1 - The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Chanson International Holding due to allegations of materially misleading business information [1][3] - Investors who purchased Chanson International securities may be entitled to compensation through a class action without any out-of-pocket fees [2] - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Aldeyra Therapeutics, Inc. received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for reproxalap, indicating a lack of substantial evidence for the drug's efficacy in treating dry eye disease [3]. - Following the FDA's announcement, Aldeyra's stock price fell by $2.99 per share, representing a 70.7% decline, closing at $1.24 per share on March 17, 2026 [3]. Group 2: Legal Actions - Investors who purchased Aldeyra securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and being recognized for its success in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. due to allegations of materially misleading business information issued to the investing public [1] Company Summary - Aldeyra Therapeutics, Inc. is facing scrutiny for potentially misleading information that may have affected its securities [1] - Shareholders who purchased Aldeyra securities may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [1]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of SYLA Technologies Co., Ltd. due to allegations of materially misleading business information issued by the company [1] Group 1 - The investigation is focused on SYLA Technologies Co., Ltd. (NASDAQ: SYT) [1] - Shareholders who purchased SYLA Technologies securities may be entitled to compensation without any out-of-pocket fees or costs [1]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Elauwit Connection, Inc. due to allegations of materially misleading business information issued to the investing public [1] Group 1: Legal Action and Investor Rights - Shareholders who purchased Elauwit securities may be entitled to compensation through a contingency fee arrangement, with a class action being prepared to recover investor losses [2] - Interested investors can join the prospective class action by submitting a form or contacting the law firm directly [2] Group 2: Company Financial Reporting Issues - On February 27, 2026, Elauwit filed a Current Report with the SEC, announcing non-reliance on previously issued interim financial statements due to an error in revenue recognition related to a network construction project [3] - The stock price of Elauwit fell by $0.52 per share, or 6.8%, closing at $7.12 per share following the announcement [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in securities class action settlements [4]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. due to allegations of materially misleading business information issued to the investing public [1] Company Summary - Disc Medicine, Inc. is facing scrutiny for potentially misleading information that may have affected its securities [1] - Shareholders who purchased Disc Medicine securities may be entitled to compensation without any out-of-pocket fees or costs through a contingency [1]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Immutep Ltd. due to allegations of materially misleading business information issued by the company [1]. Group 1: Class Action Details - Investors who purchased Immutep securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - The law firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Recent Company Developments - On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III study for eftilagimod alfa in non-small cell lung cancer, following a recommendation from the Independent Data Monitoring Committee based on a futility analysis [3]. - Following this announcement, Immutep's American Depositary Receipt price fell by $2.28, or 82.6%, closing at $0.48 per ADR on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of SES AI Corporation due to allegations that Barclays may have issued materially misleading business information to the investing public [1] Group 1 - The investigation is focused on SES AI Corporation (NYSE: SES) and its shareholders [1] - Shareholders who purchased SES AI Corporation securities may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [1]